Risk of venous thromboembolism in women with endometriosis

H. M. G. Wiegers; L. J. J. Scheres; L. Tahir; B. A. Hutten; S. Middeldorp; V. Mijatovic

doi:https://doi.org/10.1016/j.thromres.2022.07.014

Risk of venous thromboembolism in women with endometriosis

H. M. G. Wiegers, L. J. J. Scheres, L. Tahir, B. A. Hutten, S. Middeldorp, V. Mijatovic

Research output: Contribution to journal › Letter › Academic › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	104-106
Number of pages	3
Journal	Thrombosis research
Volume	217
DOIs	https://doi.org/10.1016/j.thromres.2022.07.014
Publication status	Published - 1 Sept 2022

Keywords

Endometriosis
Hormones
Risk
Thrombosis
Women

Access to Document

https://doi.org/10.1016/j.thromres.2022.07.014

Cite this

@article{6cf451e9bc274fa3b67fd59c496e61df,

title = "Risk of venous thromboembolism in women with endometriosis",

keywords = "Endometriosis, Hormones, Risk, Thrombosis, Women",

author = "Wiegers, {H. M. G.} and Scheres, {L. J. J.} and L. Tahir and Hutten, {B. A.} and S. Middeldorp and V. Mijatovic",

note = "Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: HW and LT have nothing to declare. BAH reports receiving a research grant from Silence Therapeutics outside the scope of this work. SM reports grants and personal fees from Bayer, BMS Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Portola, all during the conduct of the study; personal fees form Abbvie, personal fees from Sanofi, all outside the scope of the submitted work. LS received funding for the printing of his doctoral thesis (2019) from the Dutch Heart Foundation, Dutch Federation of Coagulation Clinics, Stichting tot Steun Promovendi Vasculaire Geneeskunde, Bayer, Daiichi Sankyo, LEO Pharma, and Pfizer, outside the scope of this work. VM reports receiving research grants from Ferring, Merck and Guerbet outside the scope of this work.",

year = "2022",

month = sep,

day = "1",

doi = "https://doi.org/10.1016/j.thromres.2022.07.014",

language = "English",

volume = "217",

pages = "104--106",

journal = "Thrombosis research",

issn = "0049-3848",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Risk of venous thromboembolism in women with endometriosis

AU - Wiegers, H. M. G.

AU - Scheres, L. J. J.

AU - Tahir, L.

AU - Hutten, B. A.

AU - Middeldorp, S.

AU - Mijatovic, V.

N1 - Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: HW and LT have nothing to declare. BAH reports receiving a research grant from Silence Therapeutics outside the scope of this work. SM reports grants and personal fees from Bayer, BMS Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Portola, all during the conduct of the study; personal fees form Abbvie, personal fees from Sanofi, all outside the scope of the submitted work. LS received funding for the printing of his doctoral thesis (2019) from the Dutch Heart Foundation, Dutch Federation of Coagulation Clinics, Stichting tot Steun Promovendi Vasculaire Geneeskunde, Bayer, Daiichi Sankyo, LEO Pharma, and Pfizer, outside the scope of this work. VM reports receiving research grants from Ferring, Merck and Guerbet outside the scope of this work.

PY - 2022/9/1

Y1 - 2022/9/1

KW - Endometriosis

KW - Hormones

KW - Risk

KW - Thrombosis

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85135566140&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.thromres.2022.07.014

DO - https://doi.org/10.1016/j.thromres.2022.07.014

M3 - Letter

C2 - 35932497

SN - 0049-3848

VL - 217

SP - 104

EP - 106

JO - Thrombosis research

JF - Thrombosis research

ER -

Risk of venous thromboembolism in women with endometriosis

Keywords

Access to Document

Other files and links

Cite this